Primary testicular lymphoma is an uncommon entity, but among lymphomas that arise primarily in the testis, diffuse large B-cell lymphoma is by far the most common subtype. It tends to affect older men, behaves aggressively, and carries a well-known propensity to spread to the central nervous system, which is why standard care has evolved into a multimodal package. That package typically begins with radical orchiectomy, the surgical removal of the affected testis, followed by rituximab-based chemotherapy, prophylactic radiotherapy to the contralateral testis, and intrathecal or systemic central nervous system prophylaxis. Each element was adopted at a different time and on the basis of different bodies of evidence, which is precisely what makes isolating the contribution of any single component so difficult.

Rituximab itself is one of the most successful targeted therapies in oncology. The monoclonal antibody binds CD20, a surface molecule found on normal and malignant B cells, and recruits the immune system to destroy them. Its addition to chemotherapy transformed outcomes in diffuse large B-cell lymphoma generally, and it is a cornerstone of modern treatment for the disease. But primary testicular DLBCL is a distinct clinical scenario: an extranodal site with unique pharmacological challenges, since the blood-testis barrier may limit drug penetration, and a pattern of relapse that favors the opposite testis and the brain. Whether the survival gains demonstrated in nodal DLBCL translate cleanly to this niche has remained an open question that no randomized trial has answered.

To address that gap, the Qingdao team, led by Kaiyue Liu and corresponding authors Zhihe Liu and Xia Zhao, conducted a comprehensive search across English and Chinese databases, including PubMed, Embase, Web of Science, the Cochrane Library, ClinicalTrials.gov, CNKI, VIP, Wanfang, SinoMed, and ChiCTR, covering the literature from database inception through June 19, 2024. The search identified eleven retrospective comparative studies encompassing 663 patients with PT-DLBCL. The study was prospectively registered in PROSPERO under registration number CRD42024567721, and the authors report no funding and no competing interests.

The quantitative core of the meta-analysis rested on a much smaller foundation than the headline numbers suggest. Only three of the eleven studies, covering 454 patients, provided extractable hazard ratios for overall survival and progression-free survival, and only these three contributed to the pooled survival estimates. Using random-effects models, the researchers calculated a pooled hazard ratio of 0.74 for overall survival, with a 95 percent confidence interval spanning 0.45 to 1.21 and a p-value of 0.23. For progression-free survival, the pooled hazard ratio was 0.78, with a 95 percent confidence interval of 0.44 to 1.37 and a p-value of 0.38. In both cases, the confidence intervals cross the null value of 1.0, meaning the data cannot exclude either a meaningful benefit or a meaningful harm.

The direction of the point estimates is mildly encouraging for rituximab, and the authors do not dismiss that signal. But they are unusually explicit about how little weight it can bear. The pooled estimates were derived from limited retrospective evidence and were largely based on unadjusted hazard ratios, meaning they were not corrected for differences between treated and untreated patients in age, disease stage, or the intensity of the other treatment modalities they received. The authors state plainly that the results should be interpreted as descriptive summaries rather than evidence of an independent association between rituximab and survival.

This caution reflects a deeper methodological problem with retrospective comparisons in oncology. Patients treated in the rituximab era also received, on average, more refined radiotherapy techniques, more consistent central nervous system prophylaxis, and better supportive care. Survival differences between cohorts separated by calendar time may therefore reflect the broader evolution of multimodal treatment strategies rather than any rituximab-specific contribution. Disentangling the antibody from its era requires either adjustment for confounders at the individual-patient level or, ideally, randomization, neither of which the existing literature provides. The meta-analysis also evaluated complete response as an exploratory secondary endpoint, but the survival outcomes remain the primary focus of the work.

The authors’ conclusion is deliberately measured: given the limitations of the available evidence, the meta-analysis found insufficient evidence to determine the independent association between rituximab-containing frontline therapy and overall survival or progression-free survival in PT-DLBCL. Importantly, they add that these findings do not exclude a potentially clinically meaningful association. The absence of proof, in other words, is not proof of absence, and clinicians should not read the null result as a reason to abandon a drug that has reshaped lymphoma care worldwide.

What the study does provide is a roadmap for fixing the evidence base. The authors call for further well-designed studies, including multicenter registries and unified reporting standards, to clarify the association. Because PT-DLBCL is rare, no single institution will ever accumulate enough patients for a definitive trial; coordinated registries that record treatment components, stage, age, and central nervous system prophylaxis in a standardized way are the most realistic path to adjusted, multivariable estimates of each therapy’s contribution. Until such data exist, the role of rituximab in this disease rests on biological plausibility and extrapolation from other lymphoma subtypes rather than on direct evidence.

For patients and clinicians, the practical takeaway is continuity rather than change. Standard multimodal therapy for primary testicular DLBCL, including rituximab-based chemotherapy alongside surgery, prophylactic radiotherapy, and CNS prophylaxis, remains the accepted approach, and nothing in this meta-analysis argues for altering it. What the study changes is the epistemic status of that practice: the survival benefit of rituximab in this specific site, long assumed by analogy, is now formally documented as unproven. In a field where rare cancers often inherit their treatment standards from better-studied cousins, that kind of honest accounting is a small but genuine contribution, marking exactly where the evidence ends and where the next decade of research should begin.

Subject of Research: Association of rituximab-containing frontline therapy with survival outcomes in primary testicular diffuse large B-cell lymphoma

Article Title: Association of rituximab with survival outcomes in primary testicular diffuse large B-cell lymphoma: a systematic review and meta-analysis of retrospective studies

Article References: Liu, K., Liu, Z., Zhang, Y., Wang, W., & Zhao, X. (2026). Association of rituximab with survival outcomes in primary testicular diffuse large B-cell lymphoma: a systematic review and meta-analysis of retrospective studies. BMC Cancer. https://doi.org/10.1186/s12885-026-16658-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16658-z

Keywords: rituximab, primary testicular lymphoma, diffuse large B-cell lymphoma, meta-analysis, overall survival, progression-free survival, retrospective studies, CNS prophylaxis, orchiectomy, PROSPERO, BMC Cancer, lymphoma treatment